WO2019055661A1 - PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS - Google Patents

PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS Download PDF

Info

Publication number
WO2019055661A1
WO2019055661A1 PCT/US2018/050893 US2018050893W WO2019055661A1 WO 2019055661 A1 WO2019055661 A1 WO 2019055661A1 US 2018050893 W US2018050893 W US 2018050893W WO 2019055661 A1 WO2019055661 A1 WO 2019055661A1
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
preeclampsia
probes
clec4a
decorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/050893
Other languages
English (en)
French (fr)
Other versions
WO2019055661A8 (en
Inventor
Matthew Cooper
Sharat Singh
Karen A. F. COPELAND
Lyndal HESTERBERG
Amin R. MAZLOOM
Mohammad Abbasi
Richard GIULIO DEL MASTRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biora Therapeutics Inc
Original Assignee
Progenity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/646,552 priority Critical patent/US20200264188A1/en
Priority to KR1020207009958A priority patent/KR20200109293A/ko
Priority to CA3075688A priority patent/CA3075688A1/en
Priority to AU2018331400A priority patent/AU2018331400A1/en
Priority to MX2020002788A priority patent/MX2020002788A/es
Priority to CN201880059588.4A priority patent/CN111094988A/zh
Priority to SG11202002065VA priority patent/SG11202002065VA/en
Priority to EP18856306.8A priority patent/EP3682250A4/en
Priority to JP2020515010A priority patent/JP2020533595A/ja
Application filed by Progenity Inc filed Critical Progenity Inc
Priority to US16/141,881 priority patent/US20190079097A1/en
Publication of WO2019055661A1 publication Critical patent/WO2019055661A1/en
Anticipated expiration legal-status Critical
Publication of WO2019055661A8 publication Critical patent/WO2019055661A8/en
Priority to US17/234,574 priority patent/US11333672B2/en
Priority to US17/691,399 priority patent/US20220268781A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • Figure 16 is a diagram showing exemplary functional roles for various markers in the pathophysiology of preeclampsia.
  • Figure 18 lists various antibodies or other antigen-binding agents for use in some embodiments disclosed herein.
  • the sample may be obtained using any method that can provide a sample suitable for the analytical methods described herein.
  • the sample may be obtained by a non-invasive method such as a throat swab, buccal swab, bronchial lavage, urine collection, scraping of the cervix, cervicovaginal sample secretion collection (e.g. with an ophthalmic sponge such as a Weck-Cel sponge), saliva collection, or feces collection.
  • the sample may be obtained by a minimally-invasive method such as a blood draw.
  • the sample may be obtained by venipuncture.
  • obtaining a sample includes obtaining a sample directly or indirectly.
  • the methods, kits, and systems disclosed herein may comprise data pertaining to one or more samples or uses thereof.
  • the data can be representative of an amount or
  • the methods, compositions, and systems described herein may involve the detection of one or more biomarker belonging to a particular functional class of biomarkers with a connection to one or more pathophysiological features of preeclampsia (see FIG. 16, which shows various pathophysiological features or preeclampsia). While
  • FGF21 Fibroblast growth factor 21, which has been demonstrated to be expressed in placental
  • preeclampsia of a pregnant patient can be detected from no more than six biomarkers selected from Table 2, Table 3, or Table 5, and any combination thereof. In some cases, preeclampsia of a pregnant patient can be detected from no more than five biomarkers selected from Table 2, Table 3, or Table 5, and any combination thereof. In some cases, preeclampsia of a pregnant patient can be detected from no more than four biomarkers selected from Table 2, Table 3, or Table 5, and any combination thereof. In some cases, preeclampsia of a pregnant patient can be detected from no more than three biomarkers selected from Table 2, Table 3, or Table 5, and any combination thereof. In some cases, preeclampsia of a pregnant patient can be detected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 biomarkers selected from Table 2, Table 3, or Table 5, and any combination thereof.
  • the methods provided herein can comprise identifying or ruling out a condition (e.g. preeclampsia) from one or more biomarkers selected from Table 2 or Table 5, and any combination thereof ("Group 4").
  • preeclampsia of a pregnant patient can be detected from one or more biomarkers selected from Table 2 or Table 5, and any combination thereof.
  • preeclampsia of a pregnant patient can be detected from two or more biomarkers selected from Table 2 or Table 5, and any combination thereof.
  • preeclampsia of a pregnant patient can be detected from three or more biomarkers selected from Table 2 or Table 5, and any combination thereof.
  • preeclampsia of a pregnant patient can be detected from two or more biomarkers selected from CCL2, CD134, DCN, HGF, NOS3, PIGF, CD274, CDCPl, FGF- 21, TGFa, UP A, CLEC4A, CLEC4C, ZBTB16, APLPl, DPP7, GRAP2, ITGB7, PAG1, TFF2, AMN, CAPG, CLEC1A5, FES, KIM1, PGF, ERBB4, GPNMB, PPY, or SYNDl, and any combination thereof.
  • biomarkers selected from CCL2, CD134, DCN, HGF, NOS3, PIGF, CD274, CDCPl, FGF- 21, TGFa, UP A, CLEC4A, CLEC4C, ZBTB16, APLPl, DPP7, GRAP2, ITGB7, PAG1, TFF2, AMN, CAPG, CLEC1A5, FES, KIM1, PGF, ERBB4, GPNMB, PP
  • preeclampsia of a pregnant patient can be detected from no more than seven biomarkers selected from CCL2, CD134, DCN, HGF, NOS3, P1GF, CD274, CDCP1, FGF-21, TGFa, UP A, CLEC4A, CLEC4C, ZBTB16, APLPl, DPP7, GRAP2, ITGB7, PAGl, TFF2, AMN, CAPG,
  • the methods provided herein can comprise identifying or ruling out a condition (e.g. preeclampsia) from one or more biomarkers selected from Table 5.
  • preeclampsia of a pregnant patient can be detected from one or more biomarkers selected from Table 5.
  • preeclampsia of a pregnant patient can be detected from two or more biomarkers selected from Table 5.
  • preeclampsia of a pregnant patient can be detected from three or more biomarkers selected from Table 5.
  • preeclampsia of a pregnant patient can be detected from four or more biomarkers selected from Table 5.
  • preeclampsia of a pregnant patient can be detected from no more than five biomarkers selected from Table 5. In some cases, preeclampsia of a pregnant patient can be detected from no more than four biomarkers selected from Table 5. In some cases, preeclampsia of a pregnant patient can be detected from no more than three biomarkers selected from Table 5. In some cases, preeclampsia of a pregnant patient can be detected from 1, 2, 3, 4, 5, 6, 7, 8, or 9 biomarkers selected from Table 5.
  • the methods provided herein can comprise identifying or ruling out a condition (e.g. preeclampsia) from one or more biomarkers selected from Table 2.
  • preeclampsia of a pregnant patient can be detected from one or more biomarkers selected from Table 2.
  • preeclampsia of a pregnant patient can be detected from two or more biomarkers selected from Table 2.
  • preeclampsia of a pregnant patient can be detected from three or more biomarkers selected from Table 2.
  • preeclampsia of a pregnant patient can be detected from four or more biomarkers selected from Table 2.
  • the methods provided herein can comprise detecting a condition (such as preeclampsia) from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 biomarkers selected from (a), (b), or (c).
  • a condition such as preeclampsia
  • kits and compositions for monitoring a condition of a pregnant patient are methods, systems, kits and compositions for monitoring a condition of a pregnant patient.
  • the monitoring is conducted by serial testing, such as serial non-invasive tests, serial minimally-invasive tests (e.g., blood draws), or some combination thereof.
  • the monitoring is conducted by administering serial noninvasive tests or serial minimally-invasive tests (e.g., blood draws).
  • the methods, kits and systems disclosed herein can improve upon the AUP of current methods of monitoring or predicting a status or outcome of a pregnancy (e.g. preeclampsia) or identifying or ruling out a classification of a sample.
  • the AUP of the methods, kits, and systems disclosed herein can be at least about 50%, 53%, 55%, 57%, 60%, 63%, 65%, 67%, 70%, 72%, 75%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3 %, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or any range in between these values.
  • disclosure provides for a method, kit, system, or test that has a sensitivity of at least 79% and a specificity of at least 94%. In some embodiments, a method, kit, system, or test has a sensitivity of at least 82% and a specificity of at least 80%. In some embodiments, a method, kit, system of test has a sensitivity of at least 90% and a specificity of at least 80%.
  • a predefined relationship between the index and the threshold value is indicative, with a negative predictive value of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, or at least 99%, of the subject not having or developing preeclampsia when used on an unbiased population of pregnant women that have both high blood pressure and proteinuria.
  • a predefined relationship between the index and the threshold value is indicative, with a negative predictive value of at least 90%, of the subject not having or developing preeclampsia.
  • the disclosure provides for a computer-implemented method of assessing the likelihood a pregnant subject has or will develop preeclampsia within a specified period of time, comprising: (a) receiving, at a computer, expression level data derived from a plasma or serum sample from the pregnant subject; (b) applying, by the computer, a classifier algorithm to the expression level data derived from the plasma or serum sample from the pregnant subject using a classification rule or a class probability equation; and (c) using, by the computer, the classification rule or class probability equation to output a classification for the sample, wherein the classification classifies the sample as a having a probability of having preeclampsia with a negative predictive value of greater than 80 percent, wherein the pregnant subject has hypertension or proteinuria.
  • the expression level data comprises levels of proteins selected from the group consisting of Tables 2, 3, 4, and 5.
  • the classifier algorithm is logistic regression.
  • the classifier algorithm is a decision tree, random forest, Bayesian network, support vector machine, neural network, or logistic regression algorithm.
  • PI GF/ sFLT 1 /KXM 1 / CLEC4 A plus all combinations of 5 th markers (CD274 or TFF2 or ADAM12 or DCN or END or HGF or FGF21 or PAPP-A1 or FN or SYND1 or UPA or PAPP-A) were generated and their performance characteristics were compared (Table 11).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
PCT/US2018/050893 2017-09-13 2018-09-13 PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS Ceased WO2019055661A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2020515010A JP2020533595A (ja) 2017-09-13 2018-09-13 子癇前症バイオマーカならびに関連するシステムおよび方法
CA3075688A CA3075688A1 (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods
AU2018331400A AU2018331400A1 (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods
MX2020002788A MX2020002788A (es) 2017-09-13 2018-09-13 Biomarcadores de preeclampsia y sistemas y metodos relacionados.
CN201880059588.4A CN111094988A (zh) 2017-09-13 2018-09-13 先兆子痫生物标志物及相关系统和方法
SG11202002065VA SG11202002065VA (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods
EP18856306.8A EP3682250A4 (en) 2017-09-13 2018-09-13 PRECLAMPSY BIOMARKERS AND RELATED SYSTEMS AND PROCEDURES
US16/646,552 US20200264188A1 (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods
KR1020207009958A KR20200109293A (ko) 2017-09-13 2018-09-13 자간전증 바이오마커 및 관련된 시스템 및 방법
US16/141,881 US20190079097A1 (en) 2017-09-13 2018-09-25 Preeclampsia biomarkers and related systems and methods
US17/234,574 US11333672B2 (en) 2017-09-13 2021-04-19 Preeclampsia biomarkers and related systems and methods
US17/691,399 US20220268781A1 (en) 2017-09-13 2022-03-10 Preeclampsia biomarkers and related systems and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558184P 2017-09-13 2017-09-13
US62/558,184 2017-09-13

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US16/646,552 A-371-Of-International US20200264188A1 (en) 2017-09-13 2018-09-13 Preeclampsia biomarkers and related systems and methods
US16/141,881 Continuation US20190079097A1 (en) 2017-09-13 2018-09-25 Preeclampsia biomarkers and related systems and methods
US17/234,574 Continuation US11333672B2 (en) 2017-09-13 2021-04-19 Preeclampsia biomarkers and related systems and methods

Publications (2)

Publication Number Publication Date
WO2019055661A1 true WO2019055661A1 (en) 2019-03-21
WO2019055661A8 WO2019055661A8 (en) 2020-03-26

Family

ID=65723874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/050893 Ceased WO2019055661A1 (en) 2017-09-13 2018-09-13 PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS

Country Status (10)

Country Link
US (3) US20200264188A1 (https=)
EP (1) EP3682250A4 (https=)
JP (1) JP2020533595A (https=)
KR (1) KR20200109293A (https=)
CN (1) CN111094988A (https=)
AU (1) AU2018331400A1 (https=)
CA (1) CA3075688A1 (https=)
MX (1) MX2020002788A (https=)
SG (1) SG11202002065VA (https=)
WO (1) WO2019055661A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
WO2022038064A1 (en) * 2020-08-17 2022-02-24 University Of Tartu Method of prognosing preeclampsia
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7756945B2 (ja) * 2021-05-07 2025-10-21 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワース パーキンソン病をスクリーニングアウトするための血液検査
CN113724873B (zh) * 2021-08-31 2024-01-12 陕西佰美基因股份有限公司 一种基于mlp多平台校准的子痫前期风险预测方法
AU2022201995A1 (en) * 2022-01-27 2023-08-10 Speclipse, Inc. Liquid refining apparatus and diagnosis system including the same
CN114878837A (zh) * 2022-05-31 2022-08-09 国家卫生健康委科学技术研究所 与妊娠期高血压疾病诊断相关的血清预测标志物
CN117012276A (zh) * 2023-06-30 2023-11-07 佛山市妇幼保健院 子痫前期溶酶体相关生物标志物的筛选方法及其应用
CN119206371B (zh) * 2024-11-22 2025-05-13 南京红十字血液中心 一种基于机器学习的血型辅助研判方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2016132136A1 (en) * 2015-02-18 2016-08-25 Aston University Diagnostic assay and treatment for preeclampsia

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777964A (en) 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US5096830A (en) 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US5223440A (en) 1987-11-17 1993-06-29 Adeza Biomedical Corporation Ex vivo product of conception test to determine abortion
US5281522A (en) 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
US4919889A (en) 1988-09-15 1990-04-24 Aspen Diagnostics Corporation Sample collection and transport fluid composition
EP0642667B1 (en) 1991-11-04 2001-01-10 Adeza Biomedical Corporation Screening method for identifying women at increased risk for preterm delivery
WO1993009432A1 (en) 1991-11-04 1993-05-13 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5516702A (en) 1991-11-06 1996-05-14 Adeza Biomedical Corporation Screening method for identifying women at increased risk for imminent delivery
US5898005A (en) 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
JP3366978B2 (ja) 1993-02-24 2003-01-14 デイド、ベーリング、インコーポレイテッド 特異的結合性アッセイ試薬の固定化
ATE226959T1 (de) 1993-03-23 2002-11-15 Victor Voroteliak Methode zur detektion von rissen in amniomembranen bei schwangeren säugetieren
US5431171A (en) 1993-06-25 1995-07-11 The Regents Of The University Of California Monitoring fetal characteristics by radiotelemetric transmission
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5650394A (en) 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US6140099A (en) 1994-05-20 2000-10-31 The Trustees Of The University Of Pennsylvania Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
US5641636A (en) 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
JP3064015B2 (ja) 1995-01-26 2000-07-12 メルク フロスト カナダ アンド カンパニー プロスタグランジンレセプターｄｐ
WO1997016461A1 (en) 1995-10-31 1997-05-09 Maruha Corporation Monoclonal antibody specific for prostaglandin d synthetase
US6678669B2 (en) 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
FI963989L (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
EP0968430A1 (en) 1997-03-07 2000-01-05 Mount Sinai Hospital Corporation Methods to diagnose a required regulation of trophoblast invasion
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
US6126597A (en) 1998-07-22 2000-10-03 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US6149590A (en) 1998-07-22 2000-11-21 Smith; Ramada S. System for identifying premature rupture of membrane during pregnancy
US20010025140A1 (en) 1998-07-22 2001-09-27 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US7109044B1 (en) 1998-09-04 2006-09-19 Maruha Corporation Method of detection and disease state management for renal diseases
PL347508A1 (en) 1998-10-29 2002-04-08 Regents Board Of Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
JP2000249709A (ja) 1999-02-26 2000-09-14 Maruha Corp 冠血管インターベンション施行後の再狭窄の予測方法
US6126616A (en) 1999-06-21 2000-10-03 Sanyal; Mrinal K. Collection of biological products from human accessory reproductive organs by absorbent systems
WO2001014882A1 (fr) 1999-08-23 2001-03-01 Bml, Inc. Identification des proprietes d'une substance pour les recepteurs de prostaglandine d
FR2809182B1 (fr) 2000-05-18 2003-08-15 Univ Rene Descartes Detection de l'il-6 pour la prevision des risques d'accouchement premature
US20010053876A1 (en) 2000-06-15 2001-12-20 Torok Brian A. System for identifying premature rupture of membrane during pregnancy
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP3752219B2 (ja) 2000-07-21 2006-03-08 マルハ株式会社 痴呆性疾患の鑑別方法
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2001288410A1 (en) 2000-08-28 2002-03-13 Patrick G. Morand Use of blood and plasma donor samples and data in the drug discovery process
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
WO2002032958A2 (en) 2000-10-16 2002-04-25 Bayer Aktiengesellschaft Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
CA2454347A1 (en) 2001-07-18 2003-01-30 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en) 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
US20050101841A9 (en) 2001-12-04 2005-05-12 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
US20060166295A1 (en) 2002-07-01 2006-07-27 James Woods Method for determination of likelihood of occurrence of preterm labor in pregnant females
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
KR101215701B1 (ko) 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
WO2004014220A2 (en) 2002-08-13 2004-02-19 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions
EP1537420B1 (en) 2002-08-29 2010-10-06 Diagnostic Technologies Ltd. Method of diagnosis of pregnancy-related complications
JPWO2004030674A1 (ja) 2002-09-30 2006-01-26 塩野義製薬株式会社 プロスタグランジンｄ▲下２▼、プロスタグランジンｄ▲下２▼アゴニストおよびプロスタグランジンｄ▲下２▼アンタゴニストの新規用途
WO2004037206A2 (en) 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
US20040100376A1 (en) 2002-11-26 2004-05-27 Kimberly-Clark Worldwide, Inc. Healthcare monitoring system
WO2004072638A1 (en) 2003-02-05 2004-08-26 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US20040203079A1 (en) 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
US8003765B2 (en) 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
US8060195B2 (en) 2003-05-02 2011-11-15 The Johns Hopkins University Devices, systems and methods for bioimpedance measurement of cervical tissue and methods for diagnosis and treatment of human cervix
US20070054951A1 (en) 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
JP3897117B2 (ja) 2003-09-24 2007-03-22 マルハ株式会社 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法
JP4354954B2 (ja) 2003-09-26 2009-10-28 株式会社マルハニチロ水産 関節リウマチの検出又は鑑別方法及び病期又は機能障害度の判別方法
US20050131287A1 (en) 2003-12-16 2005-06-16 Kimberly-Clark Worldwide, Inc. Detection of premature rupture of the amniotic membrane
JP2008514900A (ja) 2004-07-30 2008-05-08 アデザ・バイオメデイカル・コーポレイシヨン 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US20080254479A1 (en) 2004-08-30 2008-10-16 Cervimark, Llc Methods and Kits For Predicting Risk For Preterm Labor
EP2347765B1 (en) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1839056B1 (en) 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20060166242A1 (en) 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20060257901A1 (en) * 2005-03-24 2006-11-16 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
JP2009501715A (ja) 2005-07-13 2009-01-22 イーシーアイ バイオテック インコーポレイティッド 女性の状態を評価するための基質、センサー、および方法
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7863007B2 (en) 2005-09-15 2011-01-04 Swiss Asian Property Limited Marker for prolonged rupture of membranes
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
WO2007047372A2 (en) 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US20080009552A1 (en) 2006-03-23 2008-01-10 Craig Pennell Markers of pre-term labor
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007149312A2 (en) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
BRPI0714554A2 (pt) 2006-07-25 2013-05-07 Sanofi Aventis 2-fenil-indàis como antagonistas do receptor de prostaglandina d2
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2008073491A1 (en) 2006-12-11 2008-06-19 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP5194212B2 (ja) 2006-12-26 2013-05-08 ブリガム・ヤング・ユニバーシティ 血清プロテオミクスシステムと関連する方法
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US20090058072A1 (en) 2007-08-30 2009-03-05 Shirlee Ann Weber Record sheets with integrated themes
US20100251394A1 (en) 2007-09-20 2010-09-30 The Johns Hopkins University Treatment and prevention of ischemic brain injury
US20110002866A1 (en) 2007-10-31 2011-01-06 Lubit Beverly W Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent
WO2009059259A2 (en) 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20110065139A1 (en) 2007-11-27 2011-03-17 Jacob Mullerad diagnostic device for identifying rupture of membrane during pregnancy
US20130177485A1 (en) 2007-11-27 2013-07-11 Momtec Life Ltd. Of Yazmot Haemek Diagnostic device for identifying rupture of membrane during pregnancy
DK2229358T3 (da) 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
CA2711071A1 (en) 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
WO2009090399A1 (en) 2008-01-18 2009-07-23 Argenta Discovery Limited Indoles active on crth2 receptor
WO2009094665A1 (en) 2008-01-25 2009-07-30 Perkinelmer Health Sciences, Inc. Methods for determining the risk of prenatal complications
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009097579A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009099901A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
RU2501573C2 (ru) 2008-05-16 2013-12-20 Кортера, Инк. Способ предупреждения преждевременных родов
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
FR2934681B1 (fr) 2008-07-29 2011-09-30 Bastien Karkouche Dispositif pour la capture de particules biologiques et utilisation.
WO2010017201A1 (en) 2008-08-04 2010-02-11 The Board Of Regents Of The University Of Texas System Multiplexed diagnostic test for preterm labor
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US20120004233A1 (en) 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
US20120046261A1 (en) 2009-02-27 2012-02-23 University Of Utah Research Foundation Compositions and methods for diagnosing and preventing spontaneous preterm birth
GB0905964D0 (en) 2009-04-06 2009-05-20 King S College London Marker
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
US20110090048A1 (en) 2009-09-29 2011-04-21 Li Conan K Data Transmission Device with User Identification Capability
CA2779270A1 (en) 2009-10-29 2011-05-05 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
RU2556524C2 (ru) 2009-11-12 2015-07-10 Сервиленц Инк. Устройства и способы для измерения шейки матки
CA2780976C (en) 2009-11-25 2020-03-31 Hologic, Inc. Detection of intraamniotic infection
CA2807050C (en) 2009-12-08 2019-06-18 Ozlem Equils Diagnostic biomarker to identify women at risk for preterm delivery
US8874183B2 (en) 2010-02-18 2014-10-28 The Johns Hopkins University Preterm labor monitor
AR080527A1 (es) 2010-03-16 2012-04-11 Aventis Pharma Inc Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2
MX2012010035A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2.
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
US20110237972A1 (en) 2010-03-23 2011-09-29 Robert Garfield Noninvasive measurement of uterine emg propagation and power spectrum frequency to predict true preterm labor and delivery
US20130045889A1 (en) * 2010-04-13 2013-02-21 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
EP2569253A4 (en) * 2010-05-14 2013-10-02 Beth Israel Hospital EXTRACORPORAL DEVICES AND METHOD FOR TREATING COMPLICATIONS DURING PREGNANCY
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110318308A1 (en) 2010-06-25 2011-12-29 Winthrop-University Hospital Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
EP2592992A4 (en) 2010-07-12 2014-04-23 Therasyn Sensors Inc DEVICE AND METHOD FOR IN VIVO MONITORING OF PATIENTS
US8765487B2 (en) 2010-09-01 2014-07-01 Clinical Innovations Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes
BR112013007311A2 (pt) 2010-10-01 2016-07-05 Hologic Inc tira de teste de imunoensaio para uso em um sistema de diagnóstico
US10669569B2 (en) 2010-10-15 2020-06-02 Navinci Diagnostics Ab Dynamic range methods
US20120142559A1 (en) 2010-12-06 2012-06-07 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
CA2821355A1 (en) 2011-01-31 2012-08-09 Esoterix Genetic Laboratories, Llc Methods for enriching microparticles or nucleic acids using binding molecules
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP6034394B2 (ja) * 2011-11-09 2016-11-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 切迫妊娠高血圧腎症および／またはＨＥＬＬＰ症候群の指標としてのｓＦｌｔ−１またはエンドグリン／ＰｌＧＦ比の動態
EP2812698B1 (en) 2012-02-06 2020-10-28 PerkinElmer Health Sciences Canada, Inc. Dual-acceptor time-resolved-fret
CN104487593A (zh) 2012-05-08 2015-04-01 斯坦福大学托管董事会 用于提供先兆子痫评估的方法和组合物
MX356775B (es) 2012-06-27 2018-06-13 Hoffmann La Roche Medios y metodos que aplican sflt-1/plgf o relacion de endoglina/plgf para descartar el inicio de preeclampsia en un determinado periodo de tiempo.
WO2014036440A2 (en) 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
CA2903929A1 (en) * 2013-03-04 2014-09-12 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
JP6639392B2 (ja) * 2013-12-03 2020-02-05 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 胎盤成長因子２の選択的測定法
EP3097422B1 (en) 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
WO2015148989A1 (en) 2014-03-27 2015-10-01 Wayne State University Systems and methods to identify and treat subjects at risk for obstetrical complications
EP3175239A1 (en) 2014-07-30 2017-06-07 Matthew Cooper Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
WO2016134324A1 (en) 2015-02-20 2016-08-25 Neoteryx, Llc Method and apparatus for acquiring blood for testing
US20180114600A1 (en) 2015-03-23 2018-04-26 Adelaide Research & Innovation Pty Ltd Methods and systems for determining risk of a pregnancy complication occurring
CA2998275A1 (en) 2015-09-11 2017-03-16 Universidad De Los Andes In vitro method for identifying a pregnancy related disease
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
US20190353667A1 (en) 2017-02-06 2019-11-21 Astute Medical, Inc. Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
US20190079097A1 (en) 2017-09-13 2019-03-14 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2016132136A1 (en) * 2015-02-18 2016-08-25 Aston University Diagnostic assay and treatment for preeclampsia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANAND, S. ET AL.: "Serum biomarkers predictive of pre-eclampsia", BIOMARKERS IN MEDICINE, vol. 9, no. 6, 2015, pages 563 - 575, XP009519673 *
CARTY, D. ET AL.: "Novel biomarkers for predicting preeclampsia", TRENDS IN CARDIOVASCULAR MEDICINE, vol. 18, no. 5, 2008, pages 186 - 194, XP025408144, DOI: 10.1016/j.tcm.2008.07.002 *
See also references of EP3682250A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
US11327071B2 (en) 2019-12-04 2022-05-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
WO2022038064A1 (en) * 2020-08-17 2022-02-24 University Of Tartu Method of prognosing preeclampsia

Also Published As

Publication number Publication date
MX2020002788A (es) 2020-09-14
EP3682250A4 (en) 2021-03-03
CN111094988A (zh) 2020-05-01
WO2019055661A8 (en) 2020-03-26
US11333672B2 (en) 2022-05-17
US20210293824A1 (en) 2021-09-23
US20200264188A1 (en) 2020-08-20
JP2020533595A (ja) 2020-11-19
AU2018331400A1 (en) 2020-04-02
US20220268781A1 (en) 2022-08-25
CA3075688A1 (en) 2019-03-21
EP3682250A1 (en) 2020-07-22
KR20200109293A (ko) 2020-09-22
SG11202002065VA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
US11333672B2 (en) Preeclampsia biomarkers and related systems and methods
CN103969455B (zh) 确定产前并发症风险的方法
Horgan et al. Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy
AU2010240781B2 (en) Methods for determining maternal health risks
AU2012351504C1 (en) Biomarkers and parameters for preeclampsia
US20250244317A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN106796241B (zh) 确定先兆子痫风险的方法
US20190079097A1 (en) Preeclampsia biomarkers and related systems and methods
WO2021113710A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
Shree et al. Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity
Oluwole et al. Analysis of serum placental growth factor levels in preeclamptic and normotensive pregnant women in Lagos, Nigeria: a worthwhile screening tool?
JP2017516119A (ja) 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ）
Elkahlout et al. Application of proteomics in maternal and neonatal health: advancements and future directions
US20250035646A1 (en) Biomarkers for prognosis of early onset preeclampsia
Zamudio et al. From pruritus to cholestasis: Building a statistical model and online application to predict a diagnosis prior to bile acid determination
JP2016520843A (ja) 心不全後の再入院のバイオマーカー
Hasan Ali Alanbaki et al. Assessment of kisspeptin and trappin level in Iraqi women with early pregnancy loss: a cross sectional study
Ruhle et al. Machine Learning Models for Preterm Birth Prediction Using Vaginal Microbiome Profiles in a Mexican Cohort
JP2026501110A (ja) 早発性子癇前症の予後についての多重ｓｆｌｔ－１測定
WO2026051008A1 (zh) 一种利用临床实验室数据预测子痫前期的方法及其应用
HK40129389A (zh) 用於早发型先兆子痫预後的多个sflt-1测量值
Rousseau Combining Biochemical and Ultrasonographic Markers in Predicting Preeclampsia: A Systematic Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18856306

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3075688

Country of ref document: CA

Ref document number: 2020515010

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018331400

Country of ref document: AU

Date of ref document: 20180913

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018856306

Country of ref document: EP

Effective date: 20200414